Whisper it, but we may finally be seeing the IPO window reopening in 2026. | Whisper it, but we may finally be seeing the IPO window reopening in 2026.
The FDA’s surprise refusal to even review Moderna’s mRNA flu vaccine is sending a chill through biotech: Companies are openly wondering whether the regulatory goalposts are shifting under the Trump ...
In an interview, Moderna President Stephen Hoge took questions on an FDA decision on the biotech's mRNA flu vaccine, as well ...
Carter emphasizes that women are currently serving as primary “thought leaders” in the advancement of precision medicine . In ...
Alice Zhang started Verge Genomics in 2015 to rethink the drug discovery process. In the latest Equity Talk, she shares how she's overcoming biases in the VC and biotech fields. "We're going to see a ...
Investor's Business Daily on MSN
China biotech lights up. US stocks prepare for a new powerhouse.
U.S.-based biotech stocks are closely watching the China's rapid advance into the biotech field. Will they withstand the ...
All industries, including biotechnology, are faced with a drastically different economic environment from that of four or five years ago. To get a sense of how a key biotech supplier that operates on ...
Heavyweight European venture capital firms like Novo Holdings and Sofinnova Partners have joined together to make the case for more urgently needed funding in the continent's biotech ecosystem. | In ...
NEW YORK, NY / ACCESSWIRE / December 5, 2022 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap publicly traded companies recently ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results